Exciting news from our member Vertex, as gene editing therapeutic, Casgevy, is approved for treatment of patients with Transfusion Dependent Beta Thalassemia.
The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS.
“Securing access to CASGEVY is a historic moment for people living with transfusion-dependent beta thalassemia who, for too long, have had limited options for this life-shortening disease. Through collaboration with NHS England and NICE, we have reached this landmark agreement that recognises the value a one-time treatment can provide to patients, their families and the health care system.” – Ludovic Fenaux, Senior Vice President, Vertex International.
The administration of the therapy requires experience in stem cell transplantation and the management of hemoglobinopathies; therefore, Vertex is engaging with experienced hospitals throughout England to establish a network of independently operated authorised treatment centres.
Vertex continues to work collaboratively with NICE and NHS England to ensure eligible sickle cell disease patients in England can also access this treatment as soon as possible. In the European Union, Vertex is working closely with reimbursement authorities to bring this innovative therapy to eligible SCD and TDT patients rapidly.
For more information, click here.
